Page 1 - reflections_dyslipidaemia_newsletter7_2024
P. 1
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #7 2024
TABLE OF CONTENTS
KEY ARTICLES Welcome again to the Reflections Dyslipidaemia Global
Newsletter, where an international Scientific Planning
RISK ASSESSMENT
Committee summarizes and provides expert commentary
A focused update to the 2019 NLA scientific statement on on the latest clinical and real-world evidence in the field of
Dyslipida
use of lipoprotein(a) in clinical practice. Koschinsky ML, et al. dyslipidaemia. These articles are chosen based on their
J Clin Lipidol. 2024 Mar 29:S1933-2874(24)00033-3.
significance to every day clinical practice. This newsletter
TREATMENT focuses on recent updates to risk assessment with
Is there a role for earlier use of combination therapy? lipoprotein(a), the earlier role of combination therapy, and
Revankar S, et al. Am J Prev Cardiol. 2024 Feb 15:17:100639. several articles on special populations such as young adults,
familial hypercholesterolemia, obesity, and people with
SPECIAL POPULATIONS diabetes. As with the previous newsletters, we invite you to
Primary prevention of subclinical atherosclerosis in young interact through links to short video commentaries from our
adults: JACC review topic of the week. Devesa A, et al. J Am SPC, links to videos or podcasts, along with hyperlinks to full
Coll Cardiol. 2023 Nov 28;82(22):2152-2162. articles for in-depth study and reflection.
Familial hypercholesterolaemia in children and
adolescents from 48 countries: a cross-sectional Prof. Farnier (Chair)
study. European Atherosclerosis Society Familial
Hypercholesterolaemia Studies Collaboration. Lancet. 2024 Jan SCIENTIFIC PLANNING COMMITTEE
6;403(10421):55-66.
Obesity, dyslipidemia, and cardiovascular disease: A joint Prof. Michel Farnier Prof. Augusto Lavalle
expert review from the Obesity Medicine Association and (France) Cobo
the National Lipid Association 2024. Bays HE, et al. J Clin (Argentina)
Lipidol. 2024 Apr 18:S1933-2874(24)00048-5. doi: 10.1016/j.
jacl.2024.04.001. Online ahead of print.
Prof. Miriam Sandin Prof. Lourdes Santos
Lipid-lowering in diabetes: An update. Chait A, et (Spain) (Philippines)
al. Atherosclerosis. 2023 Oct 6:117313. doi: 10.1016/j.
atherosclerosis.2023.117313. Online ahead of print.
Prof. Ahmed Shawky Prof. Marcin Welnicki
ADDITIONAL ARTICLES OF INTEREST (Egypt) (Poland)
RISK ASSESSMENT
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in
clinical practice.
Koschinsky ML, et al. J Clin Lipidol. 2024 Mar 29:S1933-2874(24)00033-3.
Since the 2019 National Lipid Association (NLA) Scientific Statement on the Use of Lipoprotein(a) in Clinical Practice was issued,
there has been additional epidemiological data to clarify the relationship between Lp(a) and CVD risk reduction.
This focused update by the NLA reviews the new emerging evidence on the role of elevated Lp(a) as a CV risk factor, provides
recommendations on the candidates for Lp(a) screening, the measurement of Lp(a), and discusses treatment options.
